PL360280A1 - Use of baculovirus vectors in gene therapy - Google Patents

Use of baculovirus vectors in gene therapy

Info

Publication number
PL360280A1
PL360280A1 PL36028001A PL36028001A PL360280A1 PL 360280 A1 PL360280 A1 PL 360280A1 PL 36028001 A PL36028001 A PL 36028001A PL 36028001 A PL36028001 A PL 36028001A PL 360280 A1 PL360280 A1 PL 360280A1
Authority
PL
Poland
Prior art keywords
gene therapy
baculovirus vectors
baculovirus
vectors
therapy
Prior art date
Application number
PL36028001A
Other languages
Polish (pl)
Inventor
Seppo Yla-Herttuala
Kari J. Airenne
Original Assignee
Ark Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ark Therapeutics Limited filed Critical Ark Therapeutics Limited
Publication of PL360280A1 publication Critical patent/PL360280A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL36028001A 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy PL360280A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0012997.3A GB0012997D0 (en) 2000-05-26 2000-05-26 Gene delivery
PCT/GB2001/002383 WO2001090390A1 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy

Publications (1)

Publication Number Publication Date
PL360280A1 true PL360280A1 (en) 2004-09-06

Family

ID=9892534

Family Applications (1)

Application Number Title Priority Date Filing Date
PL36028001A PL360280A1 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy

Country Status (13)

Country Link
EP (1) EP1283894A1 (en)
JP (1) JP2003533992A (en)
KR (1) KR20030072213A (en)
CN (1) CN1430675A (en)
AU (1) AU2001258657A1 (en)
CA (1) CA2413326A1 (en)
GB (1) GB0012997D0 (en)
HU (1) HUP0302119A3 (en)
IL (1) IL153070A0 (en)
MX (1) MXPA02011517A (en)
NO (1) NO20025657L (en)
PL (1) PL360280A1 (en)
WO (1) WO2001090390A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392837A2 (en) * 2001-05-29 2004-03-03 Ark Therapeutics Limited Gene delivery via a baculovirus vector
JP4896745B2 (en) 2004-02-02 2012-03-14 アンブレツクス・インコーポレイテツド Modified human interferon polypeptides and uses thereof
AU2005265163B2 (en) 2004-06-18 2009-10-01 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
CN101087875B (en) 2004-12-22 2012-08-22 Ambrx公司 Compositions of aminoacyl-tRNA synthetase and uses thereof
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
CA2927595C (en) 2004-12-22 2023-01-31 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CN103690936A (en) 2004-12-22 2014-04-02 Ambrx公司 Modified human growth hormone
SG165353A1 (en) 2005-06-03 2010-10-28 Ambrx Inc Improved human interferon molecules and their uses
PT2339014E (en) 2005-11-16 2015-10-13 Ambrx Inc Methods and compositions comprising non-natural amino acids
ES2465473T3 (en) 2006-09-08 2014-06-05 Ambrx, Inc. Transcription of arnt suppressor in vertebrate cells
JP5840345B2 (en) 2006-09-08 2016-01-06 アンブルックス, インコーポレイテッドAmbrx, Inc. Modified human plasma polypeptides or modified human Fc scaffold proteins and uses thereof
ATE554785T1 (en) 2007-03-30 2012-05-15 Ambrx Inc MODIFIED FGF-21 POLYPEPTIDES AND THEIR USE
JP2010525821A (en) 2007-05-02 2010-07-29 アンブルックス，インコーポレイテッド Modified IFN beta polypeptides and their use
DK2217265T3 (en) 2007-11-20 2017-07-03 Ambrx Inc Modified insulin polypeptides and their use
EP2247743B1 (en) 2008-02-08 2016-04-06 Ambrx, Inc. Modified leptin polypeptides and their uses
BRPI0916515B8 (en) 2008-07-23 2021-07-27 Ambrx Inc bovine granulocyte colony-stimulating factor polypeptide (bg-csf), pharmaceutical formulation and composition comprising the same
CN101358204B (en) * 2008-08-29 2011-05-18 浙江理工大学 Method for preparing cellular membrane and cellular organelle membrane protein after human enveloped virus budding
BRPI0919031A2 (en) 2008-09-26 2014-09-23 Ambrx Inc MICRO-ORGANISMS AND REPLICATION DEPENDENT VACCINES USING NON-NATURAL AMINO ACIDS
MX346001B (en) 2008-09-26 2017-03-01 Ambrx Inc Modified animal erythropoietin polypeptides and their uses.
CN102753573A (en) 2009-12-21 2012-10-24 Ambrx公司 Modified bovine somatotropin polypeptides and their uses
AU2010341518B2 (en) 2009-12-21 2014-01-09 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP4302783A3 (en) 2010-08-17 2024-03-13 Ambrx, Inc. Modified relaxin polypeptides and their uses
TWI480288B (en) 2010-09-23 2015-04-11 Lilly Co Eli Formulations for bovine granulocyte colony stimulating factor and variants thereof
PT3412302T (en) 2014-10-24 2021-06-09 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof
TW201837051A (en) 2017-02-08 2018-10-16 美商必治妥美雅史谷比公司 Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CN114736929B (en) * 2022-05-16 2023-06-09 睿征医药科技(武汉)有限公司 Composition, method and application for producing recombinant baculovirus in insect cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU729420B2 (en) * 1996-11-01 2001-02-01 Eurogene Limited Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
DE19735593C2 (en) * 1997-08-15 1999-08-26 Hepavec Ag Fuer Gentherapie Coat protein-modified baculovirus vector for gene therapy
AU4916299A (en) * 1998-07-24 2000-02-14 Aventis Pharma S.A. Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates

Also Published As

Publication number Publication date
WO2001090390A9 (en) 2003-01-09
AU2001258657A1 (en) 2001-12-03
CN1430675A (en) 2003-07-16
CA2413326A1 (en) 2001-11-29
KR20030072213A (en) 2003-09-13
WO2001090390A1 (en) 2001-11-29
HUP0302119A3 (en) 2005-12-28
NO20025657D0 (en) 2002-11-25
GB0012997D0 (en) 2000-07-19
MXPA02011517A (en) 2004-01-26
EP1283894A1 (en) 2003-02-19
IL153070A0 (en) 2003-06-24
NO20025657L (en) 2002-11-25
HUP0302119A2 (en) 2003-09-29
JP2003533992A (en) 2003-11-18

Similar Documents

Publication Publication Date Title
IL153070A0 (en) Use of baculovirus vectors in gene therapy
IL152549A0 (en) Vectors for ocular transduction and use thereof for genetic therapy
AU1194802A (en) DNA expression vectors and methods of use
AU2002367262A8 (en) Personal user agent
GB0003397D0 (en) Therapeutic agents
GB0004003D0 (en) Therapeutic agents
HUP0401903A3 (en) Improved use of et-743 in cancer thereapy
GB0003254D0 (en) Heterocyclic compounds and their therapeutic use
AU2002303261A8 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
GB0000564D0 (en) Therapeutic agents
GB0119025D0 (en) Compounds and their therapeutic use
EP1317271A4 (en) Therapeutic and cosmetic uses of heparanases
GB0018887D0 (en) Compound and their therapeutic use
GB0008966D0 (en) Vectors for gene therapy
GB2376943B (en) Compounds and their therapeutic use
GB0112237D0 (en) Compounds and their therapeutic use
TW423322U (en) Improved structure of massage pad
GB0017625D0 (en) Use of compounds in therapy
GB0030058D0 (en) Use of compounds in therapy
GB0012945D0 (en) Use of compounds in therapy
GB0024614D0 (en) Massage manipulation ball
GB0017028D0 (en) Peptides and their therapeutic use
GB0118627D0 (en) Use of compounds in therapy
GB0023473D0 (en) Therapeutic use and formulation
GB0018888D0 (en) Compounds and their therapeutic use

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)